Markets

Ear disease biotech Auris Medical sets terms for $76 million IPO

A generic image of a pen, a tablet and papers
Credit: Shutterstock photo

Auris Medical Holding, a biotech developing treatments for inner ear disorders, announced terms for its IPO on Monday. The Zug, Switzerland-based company plans to raise $76 million by offering 6.9 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Auris would command a fully diluted market value of $285 million.

Another biotech treating ear diseases, Otonomy (OTIC), filed for an $86 million IPO earlier this month.

Auris Medical Holding, which was founded in 2003, plans to list on the NASDAQ under the symbol EARS. Jefferies and Leerink Partners are the joint bookrunners on the deal. It is expected to price during the week of July 28, 2014.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

EARS

Other Topics

IPOs